Free Trial

Insider Selling: CeriBell, Inc. (NASDAQ:CBLL) CEO Sells 25,000 Shares of Stock

CeriBell logo with Medical background

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $17.70, for a total transaction of $442,500.00. Following the transaction, the chief executive officer owned 776,022 shares in the company, valued at $13,735,589.40. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

  • On Tuesday, June 3rd, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00.
  • On Thursday, May 15th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.96, for a total transaction of $424,000.00.
  • On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The stock was sold at an average price of $15.11, for a total transaction of $236,139.08.
  • On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00.
  • On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16.

CeriBell Stock Up 1.7%

CBLL stock traded up $0.28 during midday trading on Thursday, hitting $16.78. The company's stock had a trading volume of 15,328 shares, compared to its average volume of 285,833. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $32.75. The firm has a 50-day simple moving average of $17.52 and a 200-day simple moving average of $19.84.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. As a group, equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. purchased a new stake in CeriBell in the fourth quarter valued at $368,000. Corebridge Financial Inc. purchased a new stake in CeriBell during the fourth quarter worth about $158,000. PNC Financial Services Group Inc. purchased a new stake in CeriBell during the fourth quarter worth about $47,000. Bank of America Corp DE purchased a new stake in CeriBell during the fourth quarter worth about $498,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of CeriBell in the fourth quarter valued at about $10,750,000.

Analyst Ratings Changes

A number of research firms have weighed in on CBLL. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. BTIG Research started coverage on shares of CeriBell in a research note on Tuesday, June 24th. They issued a "buy" rating and a $30.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $32.14.

Check Out Our Latest Research Report on CeriBell

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Further Reading

Insider Buying and Selling by Quarter for CeriBell (NASDAQ:CBLL)

Should You Invest $1,000 in CeriBell Right Now?

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines